<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189848</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-4648</org_study_id>
    <secondary_id>2019-83003844-57</secondary_id>
    <secondary_id>U1111-1241-0348</secondary_id>
    <nct_id>NCT04189848</nct_id>
  </id_info>
  <brief_title>Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc</brief_title>
  <official_title>A Trial to Complare the Injection Site Pain Experience of Semaglutide 0.25 mg and Dulaglutide 0.75 mg Administered sc</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study in healthy men and women looks at the injection site experience of semaglutide and&#xD;
      dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of&#xD;
      semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will&#xD;
      be given at least 30 minutes apart, one in each side of the stomach. Participants will be in&#xD;
      the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5&#xD;
      weeks after the injections were given.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 29, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of Injection Site Pain</measure>
    <time_frame>1 minute after each injection (Day 1)</time_frame>
    <description>The intensity of injection site pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimeters (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm horizontal line. The distance (mm) between the endpoint &quot;no pain&quot; and the vertical line on the VAS was recorded and analysed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Semaglutide followed by dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide followed by semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.</description>
    <arm_group_label>Dulaglutide followed by semaglutide</arm_group_label>
    <arm_group_label>Semaglutide followed by dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Subjects will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day.</description>
    <arm_group_label>Dulaglutide followed by semaglutide</arm_group_label>
    <arm_group_label>Semaglutide followed by dulaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities. Trial-related&#xD;
             activities are any procedures that are carried out as part of the trial, including&#xD;
             activities to determine suitability for the trial.&#xD;
&#xD;
          -  Male or female, aged 18-75 years (both inclusive) at the time of signing informed&#xD;
             consent.&#xD;
&#xD;
          -  Body mass index equal to or above 25.0 kg/m^2.&#xD;
&#xD;
          -  Considered to be generally healthy based on the medical history, physical examination,&#xD;
             and the results of vital signs, electrocardiogram and clinical laboratory tests&#xD;
             performed during the screening visit, as judged by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial product(s) or related products.&#xD;
&#xD;
          -  Previous participation in trial INS-4603, INS-4582 or NN9535-4648. Participation is&#xD;
             defined as having received investigational product.&#xD;
&#xD;
          -  Female who is pregnant, breast-feeding or intends to become pregnant within 4 weeks of&#xD;
             Day 1 or is of childbearing potential and not using highly effective contraceptive&#xD;
             methods.&#xD;
&#xD;
          -  Participation in a drug study within 60 days prior to drug administration in the&#xD;
             current trial OR participation in more than 4 other drug studies in the 12 months&#xD;
             prior to drug administration in the current trial.&#xD;
&#xD;
          -  Any disorder which in the Investigator's opinion might jeopardise subject's safety,&#xD;
             evaluation of results, or compliance with the protocol.&#xD;
&#xD;
          -  Glycosylated haemoglobin (HbA1c) equal to or above 6.5 % (48 mmol/mol) at screening.&#xD;
&#xD;
          -  Supine blood pressure at screening (after resting for 5 minutes or longer) outside the&#xD;
             range of 90-160 mmHg for systolic or 45-89 mmHg for diastolic.&#xD;
&#xD;
          -  Supine pulse rate (as part of vital signs) outside the range of 40-100 beats/min after&#xD;
             resting for 5 minutes or longer at screening.&#xD;
&#xD;
          -  Use of prescription medicinal products or non-prescription drugs or herbal products,&#xD;
             except routine vitamins, topical medication, contraceptives and occasional use of&#xD;
             paracetamol (not allowed within 24 hours prior to drug administration), within 14 days&#xD;
             prior to Day 1.&#xD;
&#xD;
          -  Diagnostic test results positive for HIV-1 or HIV-2 infection.&#xD;
&#xD;
          -  Diagnostic test results positive for active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  Mental incapacity, language barriers, or unwillingness to comply with the requirements&#xD;
             of the protocol, which may preclude adequate understanding or cooperation during the&#xD;
             trial as judged by the Investigator.&#xD;
&#xD;
          -  Average intake of more than 21 units of alcohol per week for male subjects and more&#xD;
             than 14 units per week for female subjects: 1 unit of alcohol equals approximately 250&#xD;
             mL of beer, 100 mL of wine, or 35 mL of spirits).&#xD;
&#xD;
          -  Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including&#xD;
             ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and&#xD;
             alcohol) at screening and admission to the clinical research centre.&#xD;
&#xD;
          -  Use of tobacco and nicotine products, defined as any of the below:&#xD;
&#xD;
          -  Smoking more than 1 cigarette or the equivalent per day on average.&#xD;
&#xD;
          -  Not able or willing to refrain from smoking and use of nicotine substitute products&#xD;
             during the in-house period.&#xD;
&#xD;
          -  Blood donation, plasma donation, or blood draw&#xD;
&#xD;
          -  In excess of 400 mL within the past 90 days prior to the day of screening&#xD;
&#xD;
          -  In excess of 50 mL within the past 30 days prior to the day of screening&#xD;
&#xD;
          -  Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or&#xD;
             medullary thyroid carcinoma.&#xD;
&#xD;
          -  Subjects with a history of malignant neoplasms within the past 5 years prior to&#xD;
             screening will be excluded from the trial.&#xD;
&#xD;
          -  Presence or history of pancreatitis (acute or chronic; as declared by the subject or&#xD;
             reported in the medical records).&#xD;
&#xD;
          -  Subject is not able to understand and read English or Dutch, or subject is not able to&#xD;
             understand and comply with the trial requirements.&#xD;
&#xD;
          -  Subject depends on the Sponsor, the Investigator, or the study centre, or subject is&#xD;
             the Investigator or any sub-investigator, research assistant, pharmacist, study&#xD;
             coordinator, other staff, or relative thereof directly involved in the conduct of the&#xD;
             trial.&#xD;
&#xD;
          -  Vulnerable subject (e.g. person kept in detention) who may have an increased&#xD;
             likelihood of being wronged or of incurring additional harm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Snitker S, Andersen A, Berg B, van Marle S, Sparre T. Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects. Diabetes Obes Metab. 2021 Jun;23(6):1415-1419. doi: 10.1111/dom.14349. Epub 2021 Mar 18.</citation>
    <PMID>33591618</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <results_first_submitted>January 28, 2021</results_first_submitted>
  <results_first_submitted_qc>January 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2021</results_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04189848/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04189848/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at one site in the Netherlands.</recruitment_details>
      <pre_assignment_details>Participants were randomised in a 2Ã—2 scheme evenly to 4 sequences (A, B, C and D) of semaglutide product (Semaglutide 1.34 mg/mL PDS290 pre-filled pen-injector) or dulaglutide product (Trulicity 0.75 mg solution for injection in pre-filled pen) and side of injection (right/left) on abdomen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence A: Semaglutide (Right) Then Dulaglutide (Left)</title>
          <description>Participants were to receive a subcutaneous (s.c.) injection of 0.25 milligrams (mg) of semaglutide on the right side of abdomen (in treatment period 1); followed by an s.c. injection of 0.75 mg of dulaglutide product on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.</description>
        </group>
        <group group_id="P2">
          <title>Sequence B: Semaglutide (Left) Then Dulaglutide (Right)</title>
          <description>Participants were to receive an s.c. injection of 0.25 mg of semaglutide on the left side of abdomen (in treatment period 1); followed by an s.c. injection of 0.75 mg of dulaglutide on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.</description>
        </group>
        <group group_id="P3">
          <title>Sequence C: Dulaglutide (Right) Then Semaglutide (Left)</title>
          <description>Participants were to receive an s.c. injection of 0.75 mg of dulaglutide on the right side of abdomen (in treatment period 1); followed by an s.c. injection of 0.25 mg of semaglutide on the left side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.</description>
        </group>
        <group group_id="P4">
          <title>Sequence D: Dulaglutide (Left) Then Semaglutide (Right)</title>
          <description>Participants were to receive an s.c. injection of 0.75 mg of dulaglutide on the left side of abdomen (in treatment period 1); followed by an s.c. injection of 0.25 mg of semaglutide on the right side of abdomen (in treatment period 2). The 2 products were administered on the same day (Day 1) with at least 30 minutes apart from each other.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2 (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all randomised subjects who had received at least 1 injection of semaglutide or dulaglutide (included any skin contact with trial product whether the injection was completed or not).</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Participants were to receive s.c. injections of 0.25 mg semaglutide and 0.75 mg dulaglutide each from any of the sequences A/B/C/D on Day 1. The 2 products were administered at least 30 minutes apart from each other.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.9" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White + Black or African</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White + Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intensity of Injection Site Pain</title>
        <description>The intensity of injection site pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimeters (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm horizontal line. The distance (mm) between the endpoint &quot;no pain&quot; and the vertical line on the VAS was recorded and analysed.</description>
        <time_frame>1 minute after each injection (Day 1)</time_frame>
        <population>The per protocol (PP) set included all participants who had received both injections of semaglutide and dulaglutide and had completed both intensity of injection site pain assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide</title>
            <description>Participants were to receive an s.c. injection of 0.25 mg of semaglutide on either (left or right) sides of abdomen in any of the sequences A/B/C/D on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide</title>
            <description>Participants were to receive an s.c. injection of 0.75 mg of dulaglutide on either (left or right) sides of abdomen in any of the sequences A/B/C/D on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Injection Site Pain</title>
          <description>The intensity of injection site pain was measured on a visual analogue scale (VAS). The VAS consists of a horizontal 100 millimeters (mm) line where 0 mm corresponded to no pain and 100 mm corresponded to unbearable pain. After each injection, the participants rated their pain perception at the VAS by marking a vertical line across the 100 mm horizontal line. The distance (mm) between the endpoint &quot;no pain&quot; and the vertical line on the VAS was recorded and analysed.</description>
          <population>The per protocol (PP) set included all participants who had received both injections of semaglutide and dulaglutide and had completed both intensity of injection site pain assessments.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="10.1"/>
                    <measurement group_id="O2" value="11.5" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intensity of injection site pain was analysed by a fixed analysis of variance model with VAS pain score as the dependent variable, and product, injection side (right side, left side), injection number (first injection, second injection), and participant as fixed effects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Treatment comparison</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Treatment difference</param_type>
            <param_value>-5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>-3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to Day 28. Results are based on the safety analysis set which included all participants who had received at least 1 injection of semaglutide or dulaglutide (included any skin contact with trial product whether the injection was completed or not).</time_frame>
      <desc>All presented adverse events are treatment emergent adverse events (TEAEs). TEAE was defined as an event that had onset date on or after the day of first injection and no later than 28 days after the day of last injection. The trial was crossover and injections were given only 30 minutes apart. Therefore it was not possible to say which product the AE was related to. Hence, AE data are presented for the overall study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>Participants were to receive s.c. injections of 0.25 mg semaglutide and 0.75 mg dulaglutide each from any of the sequences A/B/C/D on Day 1. The 2 products were administered at least 30 minutes apart from each other.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Reporting Anchor and Disclosure (1452)</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <phone>(+1) 866-867-7178</phone>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

